The PTAB has granted Celltrion’s petition for inter partes review of Biogen’s U.S. Patent 7,820,161. (IPR2016-01614) The patent is drawn to methods of treating rheumatoid arthritis by administration of rituximab. Rituximab is sold by Biogen and Genentech under the trade-name Rituxan®. Rituxan is FDA approved to treat non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
This institution decision is posted along with other important IPR filings on biologic patents on our IPR tracker page.
The post PTAB Institutes Review of Biogen’s Rituximab Patent appeared first on Big Molecule Watch.